目的 探討津力達(dá)顆粒聯(lián)合格列本脲片治療妊娠期糖尿病的臨床療效。方法 將邢臺(tái)市中心醫(yī)院在2023年3月—2024年12月收治的88例妊娠期糖尿病患者作為研究對(duì)象，按隨機(jī)數(shù)字表法將患者分為對(duì)照組和治療組，每組各44例。對(duì)照組患者口服格列本脲片，首次劑量2.5 mg/d，7 d后遞增為5 mg/d，早午餐前口服，2.5 mg/次。治療組在對(duì)照組基礎(chǔ)上口服津力達(dá)顆粒，1袋/次，3次/d。兩組患者持續(xù)治療1個(gè)月。比較兩組患者的臨床療效、血糖指標(biāo)和血清指標(biāo)。結(jié)果 治療后，對(duì)照組的總有效率為77.27%，治療組的總有效率為93.18%，組間比較差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）。治療后，兩組的空腹血糖（FBG）、平均血糖波動(dòng)幅度（MAGE）、胰島素抵抗指數(shù)（HOMA-IR）均明顯減?。?i>P＜0.05），且治療組的FBG、MAGE、HOMA-IR明顯低于對(duì)照組（P＜0.05）。治療后，兩組的血清半乳糖凝聚素-13（Gal-13）、分泌型卷曲蛋白5（SFRP5）水平明顯升高，血清成纖維細(xì)胞生長(zhǎng)因子-21（FGF-21）水平明顯降低（P＜0.05）；治療組的血清Gal-13、SFRP5水平高于對(duì)照組，血清FGF-21水平低于對(duì)照組（P＜0.05）。結(jié)論 津力達(dá)顆粒聯(lián)合格列本脲片可提高妊娠期糖尿病的臨床療效，明顯降低血糖水平和胰島素抵抗，調(diào)節(jié)血清Gal-13、SFRP5、FGF-21水平。

Objective To explore the clinical efficacy of Jinlida Granules combined with Glibenclamide Tablets in treatment of gestational diabetes mellitus. Methods A total of 88 patients with gestational diabetes mellitus who were admitted to Xingtai Central Hospital from March 2023 to December 2024 were divided into control group and treatment group according to the random number table method, with 44 cases in each group. Patients in the control group were po administered with Glibenclamide Tablets at an initial dose of 2.5 mg/d, which gradually increased to 5 mg/d after 7 d, and were taken orally before breakfast and lunch at a dose of 2.5 mg/time. The treatment group were po administered with Jinlida Granules on the basis of the control group, 1 bag/time, 3 times daily. Two groups of patients received continuous treatment for one month. The clinical efficacy, blood glucose indicators, and serum indicators were compared between two groups. Results After treatment, the total effective rate of the control group was 77.27%, while the total effective rate of the treatment group was 93.18%, and the difference between the two groups was significant (P < 0.05). After treatment, FBG, MAGE, and HOMA-IR of both groups were significantly decreased (P < 0.05), and FBG, MAGE, and HOMA-IR of the treatment group were significantly lower than those of the control group (P < 0.05). After treatment, the serum levels of Gal-13 and SFRP5 in both groups were significantly increased, while the serum levels of FGF-21 were significantly decreased (P < 0.05). The serum levels of Gal-13 and SFRP5 in the treatment group were higher than those in the control group, while the serum level of FGF-21 was lower than that in the control group (P < 0.05). Conclusion Jinlida Granules and Glibenclamide Tablets can improve the clinical efficacy in treatment of gestational diabetes mellitus, significantly reduce blood glucose levels and insulin resistance, and regulate serum levels of Gal-13, SFRP5, and FGF-21.

R977

邢臺(tái)市重點(diǎn)研發(fā)計(jì)劃自籌項(xiàng)目（2022ZC110）